Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEXX LABORATORIES INC /DEIDXX · Entity 3057 | Executive Vice President | March 03, 2026 | March 05, 2026 |
| VEEVA SYSTEMS INCVEEV · Entity 2124 | Director | June 01, 2025 | June 02, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEXX LABORATORIES INC /DE
Report date March 03, 2026 · Filed March 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 18,140.944 |
Reported balance
After 2026-03-03 transaction · row 1
1 source rowRow 1 · 2026-03-03 · Sale · Disposed 1,758 · Balance 18,140.944 F1: Represents the weighted average price of the shares sold ranging from a low of $634.5301 to a high of $634.8201 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. |
| Common StockSEC Table I · non-derivative | Indirectjointly with spouse | 160 |
Reported balance
Holding disclosure · report date 2026-03-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 160 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the weighted average price of the shares sold ranging from a low of $634.5301 to a high of $634.8201 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
VEEVA SYSTEMS INC
Report date June 01, 2025 · Filed June 02, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 4,202 |
Reported balance
After 2025-06-01 transaction · row 1
1 source rowRow 1 · 2025-06-01 · Exercise / conversion · Acquired 343 · Balance 4,202 F1: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-06-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-06-01 · Exercise / conversion · Disposed 343 · Balance 0 F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3: On June 19, 2024, the Reporting Person was granted 1,371 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2024, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act.
F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer.
F3: On June 19, 2024, the Reporting Person was granted 1,371 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2024, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2026 Filed Mar 5, 2026 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,758 | $634.57 | $1,115,577.22 |
DisclosureSEC source: 0000874716-26-000049 · wk-form4_1772748086.xml · nonDerivative · entry 1 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,140.944 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $634.5301 to a high of $634.8201 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 26, 2026 Filed Feb 27, 2026 22:03 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,693 | $661.54 | $1,781,530.72 |
DisclosureSEC source: 0000874716-26-000041 · wk-form4_1772229804.xml · nonDerivative · entry 1 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,898.944 F1 · price: Represents the weighted average price of the shares sold ranging from a low of $661.35 to a high of $661.8275 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 1,508 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000021 · wk-form4_1771374631.xml · derivative · entry 16 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,508 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in one installment on February 14, 2026. F11 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in one installment on February 14, 2026. F11 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in one installment on February 14, 2026. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 367 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000021 · wk-form4_1771374631.xml · derivative · entry 15 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,101 Underlying: Common Stock · 367 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026. F10 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026. F10 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2026. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 301 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000021 · wk-form4_1771374631.xml · derivative · entry 14 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 602 Underlying: Common Stock · 301 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025. F9 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025. F9 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments beginning on February 14, 2025. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 207 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000021 · wk-form4_1771374631.xml · derivative · entry 13 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 207 Underlying: Common Stock · 207 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024. F8 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024. F8 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 204 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000021 · wk-form4_1771374631.xml · derivative · entry 12 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 204 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments, beginning February 14, 2023. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments, beginning February 14, 2023. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock that vested in four annual installments, beginning February 14, 2023. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 1,154 | $629.35 | $726,269.90 |
DisclosureSEC source: 0000874716-26-000021 · wk-form4_1771374631.xml · nonDerivative · entry 6 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,591.944 F2 · price: Closing price of Issuer common stock on Nasdaq Global Select Market on February 13, 2026. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 367 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000021 · wk-form4_1771374631.xml · nonDerivative · entry 5 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,745.944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 1,508 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000021 · wk-form4_1771374631.xml · nonDerivative · entry 4 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,378.944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 301 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000021 · wk-form4_1771374631.xml · nonDerivative · entry 3 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,870.944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 207 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000021 · wk-form4_1771374631.xml · nonDerivative · entry 2 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,569.944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 204 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000021 · wk-form4_1771374631.xml · nonDerivative · entry 1 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,362.944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: 1. Includes 10 shares purchased under the Issuer Employee Stock Purchase Plan ('ESPP') on December 31, 2025. There are a total of 401.944 shares held in the ESPP which has been increased by 0.005 shares due to a rounding calculation of previously issued fractional shares. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 1,620 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000021 · wk-form4_1771374631.xml · derivative · entry 11 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,620 Underlying: Common Stock · 1,620 shares Expires not disclosed F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in three annual installments, beginning February 14, 2027. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in three annual installments, beginning February 14, 2027. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in three annual installments, beginning February 14, 2027. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantRestricted Stock Unit · Derivative | 1,094 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-26-000021 · wk-form4_1771374631.xml · derivative · entry 10 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,094 Underlying: Common Stock · 1,094 shares Expires not disclosed F5 · derivative.exercise_price: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock that vests in four annual installments, beginning February 14, 2027. F5 · derivative.exercise_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock that vests in four annual installments, beginning February 14, 2027. F5 · derivative.expiration_date: Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock that vests in four annual installments, beginning February 14, 2027. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantIncentive Stock Option (right-to-buy) · Derivative | 162 | $0.00 Strike: $617.20 | $0.00 |
DisclosureSEC source: 0000874716-26-000021 · wk-form4_1771374631.xml · derivative · entry 9 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 162 Underlying: Common Stock · 162 shares Expires 2036-02-11 F4 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2030. Read SEC document |
| February 12, 2026 Filed Feb 18, 2026 00:30 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | GrantNon-Qualified Stock Option (right-to-buy) · Derivative | 4,625 | $0.00 Strike: $617.20 | $0.00 |
DisclosureSEC source: 0000874716-26-000021 · wk-form4_1771374631.xml · derivative · entry 8 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,625 Underlying: Common Stock · 4,625 shares Expires 2036-02-11 F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2027. Read SEC document |
| November 07, 2025 Filed Nov 10, 2025 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 5,405 | $0.00 Strike: $505.53 | $0.00 |
DisclosureSEC source: 0000874716-25-000168 · wk-form4_1762812070.xml · derivative · entry 9 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,604 Underlying: Common Stock · 5,405 shares Expires 2032-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2023. Read SEC document |
| November 07, 2025 Filed Nov 10, 2025 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 7,125 | $0.00 Strike: $288.78 | $0.00 |
DisclosureSEC source: 0000874716-25-000168 · wk-form4_1762812070.xml · derivative · entry 8 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,125 shares Expires 2030-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that vested in four annual installments beginning February 14, 2021. Read SEC document |
| November 07, 2025 Filed Nov 10, 2025 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,378 | $705.54 | $972,240.73 |
DisclosureSEC source: 0000874716-25-000168 · wk-form4_1762812070.xml · nonDerivative · entry 6 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,148.9435 F5 · price: Represents the weighted average price of the shares sold ranging from a low of $705.26 to a high of $705.92 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 07, 2025 Filed Nov 10, 2025 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,468 | $704.87 | $1,034,743.14 |
DisclosureSEC source: 0000874716-25-000168 · wk-form4_1762812070.xml · nonDerivative · entry 5 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,526.9435 F4 · price: Represents the weighted average price of the shares sold ranging from a low of $704.235 to a high of $705.175 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 07, 2025 Filed Nov 10, 2025 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,465 | $703.73 | $1,030,970.16 |
DisclosureSEC source: 0000874716-25-000168 · wk-form4_1762812070.xml · nonDerivative · entry 4 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,994.9435 F3 · price: Represents the weighted average price of the shares sold ranging from a low of $703.05 to a high of $703.97 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 07, 2025 Filed Nov 10, 2025 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 5,114 | $702.20 | $3,591,059.49 |
DisclosureSEC source: 0000874716-25-000168 · wk-form4_1762812070.xml · nonDerivative · entry 3 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,459.9435 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $702.00 to a high of $703.00 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| November 07, 2025 Filed Nov 10, 2025 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 5,405 | $505.53 | $2,732,389.65 |
DisclosureSEC source: 0000874716-25-000168 · wk-form4_1762812070.xml · nonDerivative · entry 2 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,573.9435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 07, 2025 Filed Nov 10, 2025 22:01 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 7,125 | $288.78 | $2,057,557.50 |
DisclosureSEC source: 0000874716-25-000168 · wk-form4_1762812070.xml · nonDerivative · entry 1 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,168.9435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 11 shares purchased under the Issuer Employee Stock Purchase Plan on September 30, 2025. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 21:17 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 183 | $0.00 Strike: $544.08 | $0.00 |
DisclosureSEC source: 0000874716-25-000137 · wk-form4_1755119819.xml · derivative · entry 8 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 183 shares Expires 2031-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that became exercisable in one installment on February 14, 2025. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 21:17 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 483 | $0.00 Strike: $206.94 | $0.00 |
DisclosureSEC source: 0000874716-25-000137 · wk-form4_1755119819.xml · derivative · entry 7 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 483 shares Expires 2029-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that became exercisable in one installment on February 14, 2024. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 21:17 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionIncentive Stock Option (right-to-buy) · Derivative | 560 | $0.00 Strike: $178.26 | $0.00 |
DisclosureSEC source: 0000874716-25-000137 · wk-form4_1755119819.xml · derivative · entry 6 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 560 shares Expires 2028-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that became exercisable in one installment on February 14, 2023. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 21:17 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 183 | $544.08 | $99,566.64 |
DisclosureSEC source: 0000874716-25-000137 · wk-form4_1755119819.xml · nonDerivative · entry 4 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,032.9435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 21:17 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 483 | $206.94 | $99,952.02 |
DisclosureSEC source: 0000874716-25-000137 · wk-form4_1755119819.xml · nonDerivative · entry 3 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,849.9435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2025 Filed Aug 13, 2025 21:17 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 560 | $178.26 | $99,825.60 |
DisclosureSEC source: 0000874716-25-000137 · wk-form4_1755119819.xml · nonDerivative · entry 2 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,366.9435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 11, 2025 Filed Aug 13, 2025 21:17 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,200 | $656.53 | $787,840.20 |
DisclosureSEC source: 0000874716-25-000137 · wk-form4_1755119819.xml · nonDerivative · entry 1 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,806.9435 Read SEC document |
| August 06, 2025 Filed Aug 9, 2025 01:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 5,711 | $0.00 Strike: $206.94 | $0.00 |
DisclosureSEC source: 0000874716-25-000127 · wk-form4_1754701209.xml · derivative · entry 10 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,711 shares Expires 2029-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that became exercisable in five annual installments beginning February 14, 2020. Read SEC document |
| August 06, 2025 Filed Aug 9, 2025 01:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 5,865 | $0.00 Strike: $178.26 | $0.00 |
DisclosureSEC source: 0000874716-25-000127 · wk-form4_1754701209.xml · derivative · entry 9 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,865 shares Expires 2028-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that became exercisable in five annual installments beginning February 14, 2019. Read SEC document |
| August 06, 2025 Filed Aug 9, 2025 01:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionNon-Qualified Stock Option (right-to-buy) · Derivative | 1,218 | $0.00 Strike: $141.60 | $0.00 |
DisclosureSEC source: 0000874716-25-000127 · wk-form4_1754701209.xml · derivative · entry 8 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,218 shares Expires 2027-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Grant of option to buy shares of Issuer common stock that became exercisable in five annual installments beginning February 14, 2018. Read SEC document |
| August 06, 2025 Filed Aug 9, 2025 01:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 1,218 | $630.69 | $768,179.32 |
DisclosureSEC source: 0000874716-25-000127 · wk-form4_1754701209.xml · nonDerivative · entry 6 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,006.9435 Read SEC document |
| August 06, 2025 Filed Aug 9, 2025 01:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 2,907 | $630.91 | $1,834,051.59 |
DisclosureSEC source: 0000874716-25-000127 · wk-form4_1754701209.xml · nonDerivative · entry 5 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,224.9435 F2 · price: Represents the weighted average price of the shares sold ranging from a low of $630.50 to a high of $630.94 per share. The undersigned undertakes, upon request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price. Read SEC document |
| August 06, 2025 Filed Aug 9, 2025 01:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | SaleCommon Stock | 3,018 | $629.87 | $1,900,932.57 |
DisclosureSEC source: 0000874716-25-000127 · wk-form4_1754701209.xml · nonDerivative · entry 4 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,131.9435 Read SEC document |
| August 06, 2025 Filed Aug 9, 2025 01:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 5,711 | $206.94 | $1,181,834.34 |
DisclosureSEC source: 0000874716-25-000127 · wk-form4_1754701209.xml · nonDerivative · entry 3 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,149.9435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2025 Filed Aug 9, 2025 01:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 5,865 | $178.26 | $1,045,494.90 |
DisclosureSEC source: 0000874716-25-000127 · wk-form4_1754701209.xml · nonDerivative · entry 2 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,438.9435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 06, 2025 Filed Aug 9, 2025 01:00 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionCommon Stock | 1,218 | $141.60 | $172,468.80 |
DisclosureSEC source: 0000874716-25-000127 · wk-form4_1754701209.xml · nonDerivative · entry 1 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,573.9435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes a total of 28.7090 shares purchased under the Issuer Employee Stock Purchase Plan on March 31, 2025 and June 30, 2025. Read SEC document |
| June 01, 2025 Filed Jun 2, 2025 23:59 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionRestricted Stock Units · Derivative | 343 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-028914 · wk-form4_1748908779.xml · derivative · entry 2 Hunt Nimrata · CIK 0001800619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 343 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3 · derivative.exercise_date: On June 19, 2024, the Reporting Person was granted 1,371 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2024, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. F3 · derivative.expiration_date: On June 19, 2024, the Reporting Person was granted 1,371 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2024, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. Read SEC document |
| June 01, 2025 Filed Jun 2, 2025 23:59 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionClass A Common Stock | 343 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-028914 · wk-form4_1748908779.xml · nonDerivative · entry 1 Hunt Nimrata · CIK 0001800619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,202 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 00:13 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionRestricted Stock Units · Derivative | 342 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-009565 · wk-form4_1741047221.xml · derivative · entry 2 Hunt Nimrata · CIK 0001800619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 343 Underlying: Class A Common Stock · 342 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. F3 · derivative.exercise_date: On June 19, 2024, the Reporting Person was granted 1,371 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2024, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. F3 · derivative.expiration_date: On June 19, 2024, the Reporting Person was granted 1,371 RSUs under the Issuer's Amended & Restated 2013 Equity Incentive Plan, of which 1/4 of the RSUs vested on September 1, 2024, with the remaining RSUs vesting equally on a quarterly basis thereafter, subject to continued service on the Issuer's board of directors on the applicable vesting date. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 00:13 UTC | VEEVA SYSTEMS INC VEEV · Entity 2124 | Exercise / conversionClass A Common Stock | 342 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-009565 · wk-form4_1741047221.xml · nonDerivative · entry 1 Hunt Nimrata · CIK 0001800619 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,859 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 301 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000024 · wk-form4_1739932982.xml · derivative · entry 13 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 903 Underlying: Common Stock · 301 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning on February 14, 2025. F8 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning on February 14, 2025. F8 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning on February 14, 2025. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 207 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000024 · wk-form4_1739932982.xml · derivative · entry 12 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 414 Underlying: Common Stock · 207 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024. F7 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024. F7 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 204 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000024 · wk-form4_1739932982.xml · derivative · entry 11 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204 Underlying: Common Stock · 204 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2023. F6 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2023. F6 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2023. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Exercise / conversionRestricted Stock Unit · Derivative | 160 | $0.00 | $0.00 |
DisclosureSEC source: 0000874716-25-000024 · wk-form4_1739932982.xml · derivative · entry 10 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 160 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2022. F5 · derivative.exercise_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2022. F5 · derivative.expiration_date: Each RSU represents a contingent right to receive one share of Issuer common stock and vested in four annual installments, beginning February 14, 2022. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 02:43 UTC | IDEXX LABORATORIES INC /DE IDXX · Entity 3057 | Tax withholdingCommon Stock | 268 | $444.53 | $119,134.04 |
DisclosureSEC source: 0000874716-25-000024 · wk-form4_1739932982.xml · nonDerivative · entry 5 Hunt Nimrata · CIK 0001800619 · Executive Vice President 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,327.2345 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.